X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inrhythm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PhysIQ
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022
Details:
Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: InRhythm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: FlecIH
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Details:
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: InRhythm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Details:
Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval for the US market.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
